CVAC News and Press, CureVac N.V. From 02/10/22

- Multivalent technology approach for seasonal influenza mRNA vaccine candidate addressing four different influenza strains - Influenza candidate developed in collaboration with GSK within broad infectious disease vaccine program TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / ...

Shares of CureVac N.V. ( NASDAQ: CVAC ) closed nearly 15% down on Friday after BofA Securities said there isn’t much in the books this year for shareholders of the German biopharmaceutical company. Geoff Meacham slashed his price target to $20 In a note this morning, ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s been a rather dismal end to the week today. Indeed, many top tech stocks have been hit hard amid various economic concerns. One of the bigger losers today is CureVac  (NASDAQ: CVAC ), with CVAC st...

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / January 17, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that the company's Chief Technology Officer,...

Shares of vaccine maker CureVac (NASDAQ: CVAC) were sinking 10.8% lower as of 10:43 a.m. ET on Friday. The decline came after investment company dievini and the German government announced the signing of a revised shareholder agreement on Thursday related to their shares in CureVac....

BERLIN, GERMANY / ACCESSWIRE / January 13, 2022 / Today dievini and the Federal Republic of Germany announced the signing of a supplement to the shareholders' agreement between Kreditanstalt für Wiederaufbau (KfW) and the investment company dievini Hopp BioTech holding GmbH & Co. KG...

Newly released results from several studies on Wednesday indicated that the patients infected with the Omicron variant of coronavirus are less likely to put patients in hospitals compared to the Delta variant. In one study conducted in the U.K., data collected from Scottish hospitals by a gro...

Intercontinental Exchange will add 138 securities to the ICE Biotechnology index and delete 26 as part of the annual reconstitution, effective prior to market open on December 20. Notable additions: Aurinia Pharmaceuticals (NASDAQ:AUPH), Anavex Life Sciences (NASDAQ:AVXL), Sesen Bio...

The Nasdaq Biotechnology Index will have a new look on December 20, before the market opens when 129 securities will be added and 21 securities will be deleted as part of the annual reconstitution. Notable additions to the index: Viatris (NASDAQ:VTRS), NovoCure (NASDAQ:NVCR), Anavex Life Scie...

Direxion Launches mRNA ETF (MSGR) MSGR Offers Exposure to Rapidly Evolving mRNA Sector PR Newswire NEW YORK , Dec. 9, 2021 /PRNewswire/ -- Direxion announced today the launch of the Direxion mRNA ETF (Ticker: MSGR) . MSGR invests in companies ...